Enanta Pharmaceuticals, Inc. (ENTA) News
Filter ENTA News Items
ENTA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ENTA News Highlights
- ENTA's 30 day story count now stands at 3.
- Over the past 7 days, the trend for ENTA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest ENTA News From Around the Web
Below are the latest news stories about ENANTA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ENTA as an investment opportunity.
The Zacks Analyst Blog Highlights Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H WorldEnanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World are included in this Analyst Blog. |
Insider Sell Alert: Director Terry Vance Sells 15,295 Shares of Enanta Pharmaceuticals Inc (ENTA)In a notable insider transaction, Director Terry Vance has parted with 15,295 shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA), a significant move that warrants a closer look by investors and market analysts. |
Wall Street Analysts Predict a 108.12% Upside in Enanta Pharmaceuticals (ENTA): Here's What You Should KnowThe average of price targets set by Wall Street analysts indicates a potential upside of 108.1% in Enanta Pharmaceuticals (ENTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
How Much Upside is Left in Enanta Pharmaceuticals (ENTA)? Wall Street Analysts Think 88.23%The mean of analysts' price targets for Enanta Pharmaceuticals (ENTA) points to an 88.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx ConferenceWATERTOWN, Mass., November 22, 2023--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Evercore ISI HealthCONx Conference on November 29, 2023 at 7:55 a.m. ET in Miami, FL. |
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2023 Earnings Call TranscriptEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2023 Earnings Call Transcript November 20, 2023 Enanta Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.33, expectations were $-2.11. Operator: Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal Fourth Quarter and Year-End Financial Results Conference Call. At this time, all participants are in a listen-only mode. There will be […] |
Q4 2023 Enanta Pharmaceuticals Inc Earnings CallQ4 2023 Enanta Pharmaceuticals Inc Earnings Call |
Enanta Pharmaceuticals Inc (ENTA) Reports Fiscal Q4 and Full-Year Earnings Amid R&D FocusRevenue Declines as Company Advances Clinical Programs and Reduces Spending |
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ETWATERTOWN, Mass., November 20, 2023--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023. |
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out forEnanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |